Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus
Journal of Virological Methods, Volume 120, No. 1, Year 2004
Notification
URL copied to clipboard!
Description
There is a global need to elucidate protective antigens expressed by the SARS-coronavirus (SARS-CoV). Monoclonal antibody reagents that recognise specific antigens on SARS-CoV are needed urgently. In this report, the development and immunochemical characterisation of a panel of murine monoclonal antibodies (mAbs) against the SARS-CoV is presented, based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of 103 mAbs to the SARS virus. Subsequent screening steps reduced this panel to seventeen IgG mAbs. A single mAb, F26G15, is specific for the nucleoprotein as seen in Western immunoblot while five other mAbs react with the Spike protein. Two of these Spike-specific mAbs demonstrate the ability to neutralise SARS-CoV in vitro while another four Western immunoblot-negative mAbs also neutralise the virus. The utility of these mAbs for diagnostic development is demonstrated. Antibody from convalescent SARS patients, but not normal human serum, is also shown to specifically compete off binding of mAbs to whole SARS-CoV. These studies highlight the importance of using standardised assays and reagents. These mAbs will be useful for the development of diagnostic tests, studies of SARS-CoV pathogenesis and vaccine development. © 2004 Elsevier B.V. All rights reserved.
Authors & Co-Authors
Jones, Steven M.
Canada, Ottawa
Health Canada
Canada, Winnipeg
University of Manitoba
Dreböt, Michael A.
Canada, Winnipeg
University of Manitoba
Canada, Ottawa
Health Canada
Andonov, A.
Canada, Winnipeg
University of Manitoba
Canada, Ottawa
Health Canada
Weingartl, Hana M.
Canada, Ottawa
Canadian Food Inspection Agency Cfia
Fernando, Lisa M.
Canada, Ottawa
Health Canada
Gubbins, Michael J.
Canada, Ottawa
Health Canada
Ball, Terry Blake
Canada, Winnipeg
University of Manitoba
Kitching, Richard Paul
Canada, Ottawa
Canadian Food Inspection Agency Cfia
Li, Yan
Canada, Ottawa
Health Canada
Plummer, Francis Allan
Canada, Winnipeg
University of Manitoba
Canada, Ottawa
Health Canada
Statistics
Citations: 95
Authors: 10
Affiliations: 3
Identifiers
Doi:
10.1016/j.jviromet.2004.04.009
ISSN:
01660934
Research Areas
Covid